Nico Gagelmann

Featured in: Favicon

nature.com Favicon

jamanetwork.com Favicon

thelancet.com Favicon

ascopubs.org Favicon

bloodjournal.org Favicon

onlinelibrary.wiley.com

Articles

Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation - Bone Marrow Transplantation

Feb 5, 2024 | nature.com | Nico Gagelmann |Francis Ayuk |Christian Niederwieser

AbstractAllogeneic hematopoietic stem cell transplantation (alloHSCT) remains the only curative treatment for myelofibrosis (MF). Relapse occurs in 10–30% and remains a major factor for dismal outcomes. Previous work suggested that graft-versus-host disease (GVHD) might be associated with risk of relapse. This study included 341 patients undergoing their first (n = 308) or second (n = 33) alloHSCT. Anti-T-lymphocyte or antithymocyte globulin was used for GVHD prophylaxis in almost all patients.
Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis

Jan 7, 2024 | fis.uke.de | Nico Gagelmann |Michael Bishop |Francis Ayuk |Wolfgang Andreas Bethge

Research ExplorerPublicationsAxicabtagene ciloleucel versus tisagenlecleucel for relapsed... Abstract Bibliographical data

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →